Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer

Christopher Souder; Kim Leitzel; Suhail M. Ali; Laurence Demers; Dean B. Evans; Hilary A. Chaudri-Ross; Wolfgang Hackl; Peter Hamer; Walter Carney; Allan Lipton

doi:10.1002/cncr.22255

Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer

Cancer ◽

10.1002/cncr.22255 ◽

2006 ◽

Vol 107 (10) ◽

pp. 2337-2345 ◽

Cited By ~ 23

Author(s):

Christopher Souder ◽

Kim Leitzel ◽

Suhail M. Ali ◽

Laurence Demers ◽

Dean B. Evans ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Poor Survival ◽

Her 2 ◽

Epidermal Growth

Download Full-text

Abstract GS2-07: Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)

10.1158/1538-7445.sabcs19-gs2-07 ◽

2020 ◽

Cited By ~ 1

Author(s):

Miguel Martín ◽

Christoph Zielinski ◽

Manuel Ruíz-Borrego ◽

Eva Carrasco ◽

Eva Ciruelos ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase 3 ◽

Her 2 ◽

Epidermal Growth

Download Full-text

Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)

European Journal of Cancer ◽

10.1016/j.ejca.2021.05.025 ◽

2021 ◽

Vol 153 ◽

pp. 223-233

Author(s):

Volkmar Mueller ◽

Andrew Wardley ◽

Elisavet Paplomata ◽

Erika Hamilton ◽

Amelia Zelnak ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Epidermal Growth

Download Full-text

Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India

ecancermedicalscience ◽

10.3332/ecancer.2021.1207 ◽

2021 ◽

Vol 15 ◽

Author(s):

Anjana Joel ◽

Josh Thomas Georgy ◽

Divya Bala Thumaty ◽

Ajoy Oommen John ◽

Raju Titus Chacko ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Neoadjuvant Chemotherapy ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Patterns Of Use ◽

Epidermal Growth

Download Full-text

Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2–negative Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.09.007 ◽

2020 ◽

Vol 20 (2) ◽

pp. 160-167

Author(s):

John Smith ◽

Amy Irwin ◽

Lori Jensen ◽

Karen Tedesco ◽

Soamnauth Misir ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Eribulin Mesylate ◽

Epidermal Growth

Download Full-text

Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis

Annals of Oncology ◽

10.1093/annonc/mdw337.21 ◽

2016 ◽

Vol 27 ◽

pp. iv65

Author(s):

L. Pizzuti ◽

I. Sperduti ◽

A. Michelotti ◽

C. Omarini ◽

T. Gamucci ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Epidermal Growth

Download Full-text

Chromosome 17 Polysomy without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared with Paclitaxel in Metastatic Breast Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-1643 ◽

2010 ◽

Vol 16 (4) ◽

pp. 1281-1288 ◽

Cited By ~ 27

Author(s):

L. Downey ◽

R. B. Livingston ◽

M. Koehler ◽

M. Arbushites ◽

L. Williams ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Chromosome 17 ◽

Human Epidermal Growth Factor ◽

Epidermal Growth

Download Full-text

Efficacy and safety of bevacizumab in the treatment of human epidermal growth factor receptor type 2 negative metastatic breast cancer: About a large series in moroccan population

Indian Journal of Cancer ◽

10.4103/0019-509x.146779 ◽

2014 ◽

Vol 51 (3) ◽

pp. 272 ◽

Cited By ~ 1

Author(s):

N Majid ◽

S Boutayeb ◽

H Errihani

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Epidermal Growth

Download Full-text

Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs17-p1-09-01 ◽

2018 ◽

Cited By ~ 4

Author(s):

HS Rugo ◽

P Kabos ◽

MN Dickler ◽

WJ John ◽

I Smith ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Phase 1B ◽

Epidermal Growth

Download Full-text

Abstract P3-04-03: Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 (ERBB2) mutations in metastatic breast cancer patients

10.1158/1538-7445.sabcs17-p3-04-03 ◽

2018 ◽

Author(s):

L Jongen ◽

G Floris ◽

D Lambrechts ◽

A Laenen ◽

P Neven ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Clinical Characteristics ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Epidermal Growth

Download Full-text

Abstract P3-01-04: DETECT V – Expression analysis of human epidermal growth factor receptor 2 and estrogen receptor on circulating tumor cells of metastatic breast cancer patients

10.1158/1538-7445.sabcs18-p3-01-04 ◽

2019 ◽

Author(s):

T Fehm ◽

F Meier-Stiegen ◽

S Riethdorf ◽

B Rack ◽

F-A Taran ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Epidermal Growth Factor Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Epidermal Growth

Download Full-text